GALNT17

Summary

GALNT17 (polypeptide N-acetylgalactosaminyltransferase 17, HGNC:16347) is a protein-coding gene on chromosome 7q11.22, encoding Polypeptide N-acetylgalactosaminyltransferase 17 (Q6IS24). May catalyze the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.

This gene encodes an N-acetylgalactosaminyltransferase. This gene is located centromeric to the common deleted region in Williams-Beuren syndrome (WBS), a multisystem developmental disorder caused by the deletion of contiguous genes at 7q11.23. This protein may play a role in membrane trafficking.

Source: NCBI Gene 64409 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 89 total
• MANE Select transcript: NM_022479

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16347
Approved symbol	GALNT17
Name	polypeptide N-acetylgalactosaminyltransferase 17
Location	7q11.22
Locus type	gene with protein product
Status	Approved
Aliases	GALNTL3, GalNAc-T5L, GalNAc-T19, GalNAc-T17, ppGalNAc-T17
Ensembl gene	ENSG00000185274
Ensembl biotype	protein_coding
OMIM	615137
Entrez	64409

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000333538, ENST00000447516, ENST00000467723, ENST00000498380

RefSeq mRNA: 1 — MANE Select: NM_022479 NM_022479

CCDS: CCDS5540

Canonical transcript exons

ENST00000333538 — 11 exons

Exon	Start	End
ENSE00001303800	71712018	71713599
ENSE00001705539	71132144	71133040
ENSE00003468602	71665411	71665596
ENSE00003487520	71677211	71677306
ENSE00003537317	71335550	71335733
ENSE00003558805	71415889	71416063
ENSE00003561571	71420908	71421105
ENSE00003572329	71710761	71710928
ENSE00003590000	71669972	71670109
ENSE00003680888	71571285	71571402
ENSE00003689083	71388235	71388401

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 97.43.

FANTOM5 (CAGE): breadth broad, TPM avg 3.8350 / max 82.4151, expressed in 500 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78986	2.0951	457
78989	1.2055	343
78988	0.2329	175
78987	0.2294	150
204474	0.0721	35

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trigeminal ganglion	UBERON:0001675	97.43	gold quality
dorsal root ganglion	UBERON:0000044	96.89	gold quality
cerebellar vermis	UBERON:0004720	96.02	gold quality
prefrontal cortex	UBERON:0000451	95.35	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.94	gold quality
cerebellar cortex	UBERON:0002129	94.90	gold quality
cerebellar hemisphere	UBERON:0002245	94.87	gold quality
right frontal lobe	UBERON:0002810	94.80	gold quality
cerebellum	UBERON:0002037	94.68	gold quality
frontal cortex	UBERON:0001870	94.44	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.85	gold quality
neocortex	UBERON:0001950	93.27	gold quality
apex of heart	UBERON:0002098	93.23	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.18	gold quality
anterior cingulate cortex	UBERON:0009835	92.59	gold quality
tibial nerve	UBERON:0001323	92.47	gold quality
superior frontal gyrus	UBERON:0002661	92.27	gold quality
cerebral cortex	UBERON:0000956	92.09	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.39	gold quality
sural nerve	UBERON:0015488	91.38	gold quality
parietal lobe	UBERON:0001872	90.96	gold quality
heart left ventricle	UBERON:0002084	90.92	gold quality
cardiac ventricle	UBERON:0002082	90.41	gold quality
middle temporal gyrus	UBERON:0002771	90.27	gold quality
Ammon’s horn	UBERON:0001954	90.21	gold quality
occipital lobe	UBERON:0002021	90.20	gold quality
postcentral gyrus	UBERON:0002581	90.08	gold quality
primary visual cortex	UBERON:0002436	89.47	gold quality
pons	UBERON:0000988	89.06	gold quality
left ventricle myocardium	UBERON:0006566	89.06	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	75.40
E-CURD-119	yes	47.07
E-ANND-3	yes	4.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting GALNT17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-5007-3P	99.51	68.14	1242
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-4722-3P	99.35	65.22	1099

Literature-anchored findings (GeneRIF, showing 5)

• a subset of O-glycosylation produced by WBSCR17 controls dynamic membrane trafficking, probably between the cell surface and the late endosomes through macropinocytosis (PMID:22787146)
• GWA study identified maternal genetic effects not previously identified in ASD at a locus in WBSCR17. (PMID:27876814)
• Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. (PMID:32310270)
• Circ_WBSCR17 aggravates inflammatory responses and fibrosis by targeting miR-185-5p/SOX6 regulatory axis in high glucose-induced human kidney tubular cells. (PMID:32798559)
• Parkinson’s Disease Risk Variant rs9638616 is Non-Specifically Associated with Altered Brain Structure and Function. (PMID:38640170)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	galnt17	ENSDARG00000042418
mus_musculus	Galnt17	ENSMUSG00000034040
rattus_norvegicus	Galnt17	ENSRNOG00000024435
drosophila_melanogaster	Pgant7	FBGN0030930
drosophila_melanogaster	Pgant5	FBGN0031681
drosophila_melanogaster	Pgant6	FBGN0035375
drosophila_melanogaster	CG7304	FBGN0036527
drosophila_melanogaster	CG7579	FBGN0036528
drosophila_melanogaster	Pgant8	FBGN0036529
drosophila_melanogaster	Pgant9	FBGN0050463
drosophila_melanogaster	CG31776	FBGN0051776
drosophila_melanogaster	Pgant4	FBGN0051956
caenorhabditis_elegans		WBGENE00001628
caenorhabditis_elegans		WBGENE00001630
caenorhabditis_elegans		WBGENE00001632
caenorhabditis_elegans		WBGENE00001635

Paralogs (19): GALNT16 (ENSG00000100626), GALNTL5 (ENSG00000106648), GALNT7 (ENSG00000109586), GALNT18 (ENSG00000110328), GALNT3 (ENSG00000115339), GALNT12 (ENSG00000119514), GALNT8 (ENSG00000130035), GALNT15 (ENSG00000131386), GALNT5 (ENSG00000136542), GALNT6 (ENSG00000139629), GALNT1 (ENSG00000141429), GALNT2 (ENSG00000143641), GALNT13 (ENSG00000144278), GALNT14 (ENSG00000158089), GALNT10 (ENSG00000164574), GALNTL6 (ENSG00000174473), GALNT11 (ENSG00000178234), GALNT9 (ENSG00000182870), GALNT4 (ENSG00000257594)

Protein

Protein identifiers

Polypeptide N-acetylgalactosaminyltransferase 17 — Q6IS24 (reviewed: Q6IS24)

Alternative names: Polypeptide GalNAc transferase-like protein 3, Protein-UDP acetylgalactosaminyltransferase-like protein 3, UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-like protein 3, Williams-Beuren syndrome chromosomal region 17 protein

All UniProt accessions (3): Q6IS24, H7BZX9, Q2L4S5

UniProt curated annotations — full annotation on UniProt →

Function. May catalyze the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Highly expressed in brain and heart. Weakly expressed in kidney, liver, lung and spleen.

Disease relevance. WBSCR17 is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region.

Domain organisation. There are two conserved domains in the glycosyltransferase region: the N-terminal domain (domain A, also called GT1 motif), which is probably involved in manganese coordination and substrate binding and the C-terminal domain (domain B, also called Gal/GalNAc-T motif), which is probably involved in catalytic reaction and UDP-Gal binding. The ricin B-type lectin domain binds to GalNAc and contributes to the glycopeptide specificity.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 2 family. GalNAc-T subfamily.

RefSeq proteins (1): NP_071924* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000772	Ricin_B_lectin	Domain
IPR001173	Glyco_trans_2-like	Domain
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily
IPR035992	Ricin_B-like_lectins	Homologous_superfamily
IPR045885	GalNAc-T	Domain

Pfam: PF00535, PF00652

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a 3-O-[N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + UDP + H(+) (RHEA:23956)
• L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a 3-O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + UDP + H(+) (RHEA:52424)

UniProt features (23 total): binding site 7, disulfide bond 5, glycosylation site 3, topological domain 2, region of interest 2, chain 1, transmembrane region 1, sequence conflict 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6IS24-F1	90.68	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 248; 378; 381; 386; 192; 223; 246

Disulfide bonds (5): 142–373, 364–443, 478–494, 526–541, 568–586

Glycosylation sites (3): 50, 461, 486

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-913709	O-linked glycosylation of mucins

MSigDB gene sets: 44 (showing top): GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, CATTTCA_MIR203, MYOD_01, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, chr7q11, DOUGLAS_BMI1_TARGETS_UP, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, GRYDER_PAX3FOXO1_TOP_ENHANCERS, YGCGYRCGC_UNKNOWN, GOMF_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY, GOMF_HEXOSYLTRANSFERASE_ACTIVITY, GOMF_GLYCOSYLTRANSFERASE_ACTIVITY, GOMF_POLYPEPTIDE_N_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY

GO Biological Process (2): protein O-linked glycosylation (GO:0006493), obsolete protein glycosylation (GO:0006486)

GO Molecular Function (5): polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653), carbohydrate binding (GO:0030246), metal ion binding (GO:0046872), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
O-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	1
acetylgalactosaminyltransferase activity	1
catalytic activity, acting on a protein	1
binding	1
cation binding	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

848 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GALNT17	CALN1	Q9BXU9	516
GALNT17	AUTS2	Q8WXX7	475
GALNT17	DLGAP4	Q9Y2H0	471
GALNT17	METTL27	Q8N6F8	419
GALNT17	CLMP	Q9H6B4	408
GALNT17	B3GALNT2	Q8NCR0	406
GALNT17	KCNK12	Q9HB15	404
GALNT17	EOGT	Q5NDL2	403
GALNT17	GTF2I	P78347	388
GALNT17	GABRQ	Q9UN88	374
GALNT17	ZNF608	Q9ULD9	370
GALNT17	MAN2C1	Q9NTJ4	351
GALNT17	ASXL2	Q76L83	348
GALNT17	CCNB3	Q8WWL7	348
GALNT17	ECSCR	Q19T08	347
GALNT17	RILPL1	Q5EBL4	347

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
SAAL1	TMEM223	psi-mi:“MI:0914”(association)	0.350

BioGRID (1): WBSCR17 (Synthetic Lethality)

ESM2 similar proteins: A4IGL7, D3ZB51, E9PZ19, O75882, O94779, O95970, P00533, P02469, P07942, P13590, P15209, P24503, P24786, P33150, P39038, P55245, P55283, P68500, P97300, P97527, P97546, Q01279, Q01973, Q03351, Q16288, Q16620, Q1EGL2, Q3B7N0, Q3UQ28, Q5IFJ9, Q5IS37, Q5IS82, Q5R945, Q63604, Q6IS24, Q6VNS1, Q7TPD3, Q7TT15, Q8K4Y5, Q8N475

Diamond homologs: A8Y236, H0ZAB5, O08832, O08912, O45293, O45947, O61394, O61397, O88422, P34678, P70419, Q07537, Q10471, Q10472, Q10473, Q14435, Q29121, Q49A17, Q5EA41, Q5RFJ6, Q6DJR8, Q6IS24, Q6P6V1, Q6P9A2, Q6P9S7, Q6PB93, Q6UE39, Q6WV16, Q6WV17, Q6WV19, Q6WV20, Q7K755, Q7TT15, Q7Z4T8, Q7Z7M9, Q80VA0, Q86SF2, Q86SR1, Q8BGT9, Q8BVG5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

4747 predictions. Top by Δscore:

Variant	Effect	Δscore
7:71133036:GAATG:G	donor_gain	1.0000
7:71133039:TGGT:T	donor_loss	1.0000
7:71133040:GGTAA:G	donor_loss	1.0000
7:71133041:G:C	donor_loss	1.0000
7:71133042:T:A	donor_loss	1.0000
7:71151820:A:AG	acceptor_gain	1.0000
7:71151821:G:GA	acceptor_gain	1.0000
7:71335545:TCTA:T	acceptor_loss	1.0000
7:71335546:CTAG:C	acceptor_loss	1.0000
7:71335547:TA:T	acceptor_loss	1.0000
7:71335548:A:AG	acceptor_gain	1.0000
7:71335549:G:A	acceptor_loss	1.0000
7:71335549:G:GG	acceptor_gain	1.0000
7:71335549:GGC:G	acceptor_gain	1.0000
7:71335549:GGCT:G	acceptor_gain	1.0000
7:71335549:GGCTT:G	acceptor_gain	1.0000
7:71335729:ACCAA:A	donor_gain	1.0000
7:71335730:CCAA:C	donor_gain	1.0000
7:71335730:CCAAG:C	donor_loss	1.0000
7:71335731:CAA:C	donor_gain	1.0000
7:71335732:AA:A	donor_gain	1.0000
7:71335734:G:C	donor_loss	1.0000
7:71335734:G:GG	donor_gain	1.0000
7:71335735:T:A	donor_loss	1.0000
7:71388232:CA:C	acceptor_loss	1.0000
7:71388233:A:AG	acceptor_gain	1.0000
7:71388233:AGGT:A	acceptor_gain	1.0000
7:71388234:G:GC	acceptor_gain	1.0000
7:71388234:GGT:G	acceptor_gain	1.0000
7:71388234:GGTG:G	acceptor_gain	1.0000

AlphaMissense

3912 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:71335705:C:A	R132S	1.000
7:71335706:G:C	R132P	1.000
7:71388236:T:A	C142S	1.000
7:71388237:G:C	C142S	1.000
7:71388300:A:T	E163V	1.000
7:71388324:C:T	S171F	1.000
7:71416036:A:T	D246V	1.000
7:71416062:T:A	W255R	1.000
7:71416062:T:C	W255R	1.000
7:71420908:G:C	W255C	1.000
7:71420908:G:T	W255C	1.000
7:71421032:T:A	W297R	1.000
7:71421032:T:C	W297R	1.000
7:71421034:G:C	W297C	1.000
7:71421034:G:T	W297C	1.000
7:71571384:T:A	N354K	1.000
7:71571384:T:G	N354K	1.000
7:71665454:G:C	R375P	1.000
7:71665462:C:G	H378D	1.000
7:71665464:C:A	H378Q	1.000
7:71665464:C:G	H378Q	1.000
7:71665521:T:A	N397K	1.000
7:71665521:T:G	N397K	1.000
7:71665543:T:A	W405R	1.000
7:71665543:T:C	W405R	1.000
7:71677238:T:A	C478S	1.000
7:71677238:T:C	C478R	1.000
7:71677239:G:C	C478S	1.000
7:71677240:C:G	C478W	1.000
7:71710836:T:A	C526S	1.000

dbSNP variants (sampled 300 via entrez): RS1000002244 (7:71343661 A>G), RS1000009427 (7:71344192 C>G,T), RS1000017317 (7:71319346 G>A), RS1000024033 (7:71496590 G>A), RS1000024693 (7:71553889 C>T), RS1000027768 (7:71378776 G>C,T), RS1000037545 (7:71452497 A>G), RS1000039017 (7:71564601 C>A), RS1000043968 (7:71612485 G>A), RS1000053696 (7:71261938 C>T), RS1000056500 (7:71514900 T>G), RS1000061698 (7:71176748 T>A), RS1000063391 (7:71149243 A>T), RS1000066667 (7:71267041 A>G), RS1000067084 (7:71476307 C>T)

Disease associations

OMIM: gene MIM:615137 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST001520_18	Response to angiotensin II receptor blocker therapy	2.000000e-06
GCST001850_28	Major depressive disorder	2.000000e-06
GCST002491_4	Age-related hearing impairment	2.000000e-06
GCST002979_2	Response to montelukast in asthma (change in FEV1)	9.000000e-07
GCST003264_963	Post bronchodilator FEV1/FVC ratio	5.000000e-06
GCST003901_13	Cognitive decline (age-related)	3.000000e-06
GCST004749_19	Lung cancer in ever smokers	8.000000e-06
GCST007003_2	Cerebrospinal fluid p-tau levels in normal cognition	2.000000e-07
GCST007006_5	Logical memory (delayed recall) in normal cognition	6.000000e-07
GCST007324_154	Adventurousness	1.000000e-12
GCST007327_60	Smoking status (ever vs never smokers)	3.000000e-08
GCST008161_67	Waist circumference adjusted for body mass index	7.000000e-06
GCST008223_2	Diabetic peripheral neuropathy in type 2 diabetes	3.000000e-06
GCST009391_375	Metabolite levels	8.000000e-06
GCST011920_1	Hearing loss in noise exposure	1.000000e-06

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0005921	FEV change measurement
EFO:0004713	FEV/FVC ratio
EFO:0004763	p-tau measurement
EFO:0004874	memory performance
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0007789	BMI-adjusted waist circumference
EFO:0010436	triacylglycerol 56:9 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs7794356	Efficacy	3	montelukast	Asthma

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7794356	GALNT17	3	0.00	1	montelukast

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases methylation	4
trichostatin A	decreases expression	1
arsenite	increases methylation	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
belinostat	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Amiodarone	increases expression	1
Arsenic	affects methylation	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	increases expression	1
Cyclosporine	decreases methylation	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.